Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $2.9052W HIGH $27.00
Volume
140.98 K
Value Traded
104.84 K
Short % Float
2.85%
-27.09%Week
-43.08%1 Month
-68.78%3 Month
-56.47%6 Month
-98.23%5 Year
-98.23%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
25.14 M
EPS (TTM)
-66.04
P/E Ratio
-
Ent. Value
24.56 M
Total Shares
8.49 M
Float Shares
6.21 M
Insiders
11.67%
Institutions
9.98%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
SCLX Catalyst Timeline
Dated clinical, regulatory and corporate events for Scilex Holding Company
Catalyst Timeline
Dated clinical, regulatory & corporate events for Scilex Holding Company
321Total events
2Upcoming
77Tier-1 (high impact)
2020 to 2036Coverage
Upcoming catalysts 2
Event history 50
▲Partnership / LicenseCorporate
Semnur signs binding term sheet for $100M strategic investment from iHolding Group LLP
◆Equity OfferingCorporate
Signing of binding term sheet for $100M strategic investment from iHolding Group LLP
●Quarterly UpdateCorporate
Payment date for Dream Bowl Token dividend (within 60 days after record date)
◆Other Regulator MilestoneEx-US Regulatory
Dream Bowl I Meme Coin tokens to list on Biconomy Exchange
▲Quarterly UpdateCorporate
Board approved dividend of Semnur common stock to Scilex stockholders
▲Partnership / LicenseCorporate
ACEA Therapeutics and ACEA Pharma entered into definitive agreement with Phoenix Asia Holdings for acquisition of ACEA Pharma
●Quarterly UpdateCorporate
Board approved dividend of Dream Bowl I Meme Coin Tokens with record date April 30, 2026
◆AcquisitionCorporate
Closing of acquisition of ACEA Pharma by Phoenix Asia Holdings expected by end of Q2 2026
▲Partnership / LicenseCorporate
Scilex in-licenses worldwide exclusive license from Datavault AI for tokenization and monetization of biotech assets
◆Equity OfferingCorporate
Scilex signs SPA to exchange $200M of Semnur common stock for Bitcoin
◆Quarterly UpdateCorporate
Extraordinary general meeting of Denali shareholders to approve business combination
◆Trial InitiationSP-102FiledTrial
Second Phase 3 trial for SP-102 to be advanced with PIPE proceeds
Lumbosacral Radicular Pain (LRP)/Sciaticasource ↗
◆Timing GuidancePresentation
Business combination between Semnur and Denali expected to close
▲FDA Filing AcceptedRegulatory Filing
Registration statement on Form S-4 declared effective by SEC for business combination of Denali and Semnur
●PublicationGLOPERBAApprovedPresentation
Publication on GLOPERBA dosing adjustments in peer-review journal
prophylaxis of painful gout flaressource ↗
◆Poster PresentationSP-102FiledPresentation
Post-hoc analysis of CLEAR-1 trial on clinical meaningfulness of SP-102 for LRP at ASIPP 2025
lumbosacral radicular painsource ↗
◆Quarterly UpdateCorporate
Record date for preferred stock dividend changed from April 11, 2025 to May 2, 2025
▲Orphan Drug DesignationcolchicineApprovedDesignation
FDA granted orphan drug designation for colchicine for pericarditis
pericarditissource ↗
▲Other Regulator MilestoneELYXYBApprovedEx-US Regulatory
Health Canada approval of New Drug Submission for ELYXYB
acute treatment of migraine with or without aurasource ↗
◆Restructuring LayoffsCorporate
Bankruptcy court extends lockup on Scilex Dividend Stock to April 14, 2025
◆Quarterly UpdateCorporate
Record date for preferred stock dividend changed from January 28, 2025 to April 11, 2025
◆IP Litigation RulingZTlidoApprovedIP / Competition
Appeal filed to U.S. Court of Appeals for the Federal Circuit
postherpetic neuralgiasource ↗
◆Other Regulator MilestoneELYXYBApprovedEx-US Regulatory
Anticipated approval timeline for ELYXYB in Canada
acute treatment of migraine with or without aurasource ↗
◆Restructuring LayoffsCorporate
Bankruptcy court extends lockup on Scilex Dividend Stock to January 31, 2025
◆Quarterly UpdateCorporate
Record date for preferred stock dividend changed from November 7, 2024 to January 28, 2025
●sNDA SubmissionELYXYBApprovedRegulatory Filing
FDA acknowledged submission of sNDA for ELYXYB in acute pain indication
acute painsource ↗
▲Quarterly UpdateCorporate
Expects to receive notification of regained compliance with Nasdaq Listing Rule 5250(c)(1)
▲Partnership / LicenseGLOPERBAApprovedCorporate
Note holders intend to participate in funding and licensing of Gloperba ex-U.S. commercialization rights from Romeg Therapeutics
gout flaressource ↗
●sNDA SubmissionELYXYBApprovedRegulatory Filing
Scilex files sNDA with FDA for ELYXYB in acute pain indication
acute painsource ↗
▲Partnership / LicenseGLOPERBAApprovedCorporate
Scilex amends license agreement with Romeg for worldwide rights to commercialize Gloperba
prophylaxis of painful gout flaressource ↗
▲PublicationZTlidoApprovedPresentation
Pain Medicine News published retrospective claims data on ZTlido vs. lidocaine 5% patch
neuropathic painsource ↗
◆Quarterly UpdateCorporate
Payment date for preferred stock dividend expected within 60 days of record date
◆AcquisitionCorporate
Closing of business combination between Semnur and Denali Capital Acquisition Corp.
Past FDA Catalysts and PDUFA Decisions
How SCLX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2024-08-28 | Gloperba (colchicine) | PDUFA Date Approved | PDUFA |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D30 / 100
Pipeline Score
$8M
Pipeline Value
$32M
Commercial Value
Fair Value
Valuation Signal
4
Drugs Scored
0.8x
rNPV / MCap
Top 69%
Micro Cap(rank 454 of 658)
Percentile Rank
Scilex Holding Company faces pipeline headwinds (30/100), with $1.2B risk-adjusted pipeline value, led by SP-103 in Moderate to Severe Acute Lower Back Pain (Phase 2), but cash runway is a concern.
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Jun 2026; product lines: last four quarters to Jun 2026 (10-K and 10-Q)) Revenue $31.7M x 1.0 = $32M
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| ZTlido | $23M | $40M | -43.6% |
| ELYXYB | $4M | $4M | +3.7% |
| GLOPERBA | $0M | - | - |
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SP-103 Small moleculeCompletedNCT05096494 | Moderate to Severe Acute Lower Back Pain | Phase 2 | COMPLETED | 76 | May 30, 2023 |
Clinical Trial Results
Readouts, endpoints and source filings for every SCLX program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| SP-102 Fast Track | lumbosacral radicular pain | 2025-05-16 | clear clinically meaningful separation between SP-102 and placebo in multiple with-in subject endpointsRead More | Scilex Holding Company Presented Post-Hoc Analysis of the C.L.E.A.R. Trial on Clinical Meaningfulness of Safety and Efficacy of SP-102 for the Treatment of Lumbosacral Radicular Pain (LRP) at the 27th Annual Meeting of American Society of Interventional Pain Physicians (ASIPP), May 15-17, 2025 in Orlando, FLRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| SCLX Stock Acquisition JV LLC10% Owner | Other | -500,000 958,263 held | $0.00 | 07/03/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in SCLX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 0 % | 257.00 K | 1.04 M |
SCLX Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How SCLX ranks across every disease it competes in
Competitive Position is a premium feature
See how SCLX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialSCLX News
SCLX▲ +23%on this news
Semnur Pharmaceuticals, Inc. (“Semnur”), a Majority-Owned Subsidiary of Scilex Holding Company (Nasdaq: SCLX, “Scilex”), Announces Signing of Binding Term Sheet for Proposed $100 Million Strategic Investment from iHolding Group LLP
Semnur Pharmaceuticals has signed a binding term sheet with iHolding Group for a proposed $100 million investment. This funding aims to support the advancement of Semnur's pipeline, particularly the Phase 3 clinical program for SEMDEXA™. The investment is contingent upon due diligence and regulatory approvals, marking a significant step for Semnur's growth and innovation in non-opioid pain therapies.
Read more →SCLXScilex Holding Company Announces Dream Bowl I Meme Coin Tokens Commence Trading on the Biconomy Exchange on July 6, 2026
Scilex Holding Company announced that its Dream Bowl I Meme Coin tokens began trading on the Biconomy Exchange on July 6, 2026. This move is expected to provide liquidity and broaden the distribution of the tokens among eligible equityholders. The Biconomy Exchange is recognized for its security and extensive trading volume, which may benefit the token's market presence.
Read more →SCLXScilex Holding Company Announces Signing of Binding Term Sheet for Proposed $100 Million Strategic Investment from iHolding Group LLP
Scilex Holding Company has signed a binding term sheet for a proposed $100 million investment from iHolding Group LLP. This investment will support Scilex's strategic growth, including product development and acquisitions. The agreement is contingent upon customary due diligence and regulatory approvals. iHolding aims to bolster Kazakhstan's role in the global healthcare sector.
Read more →SCLX▼ -26%on this news
Scilex Holding Company Announces Dream Bowl I Meme Coin Tokens to List on Biconomy Exchange as Early as June 23, 2026
Scilex Holding Company has announced that its Dream Bowl I Meme Coin tokens will be listed on the Biconomy Exchange starting June 23, 2026. This listing is expected to provide liquidity and enable widespread distribution of the tokens to eligible equity holders. Scilex continues to focus on developing non-opioid pain management products.
Read more →SCLXScilex Holding Company (“Scilex”) Confirms the Previously Announced Payment Date of June 15, 2026 for the Dividend of Semnur Pharmaceuticals, Inc. Common Stock to Holders of Scilex Common Stock and other Eligible Equity Securities
Scilex Holding Company has confirmed the payment date of June 15, 2026, for the dividend of Semnur Pharmaceuticals, Inc. common stock to eligible holders of Scilex securities. The ex-dividend date is set for June 16, 2026. This announcement provides clarity for investors regarding the dividend process and highlights Scilex's ongoing commitment to developing non-opioid pain management products.
Read more →SCLX▲ +5.7%on this news
Scilex Holding Company (“Scilex”) Announces a Payment Date of June 15, 2026 for the Previously Announced Dividend of Semnur Pharmaceuticals, Inc. Common Stock to Holders of Scilex Common Stock and other Eligible Equity Securities
Scilex Holding Company announced that it will pay a dividend of Semnur Pharmaceuticals common stock to eligible shareholders on June 15, 2026. Each eligible holder will receive one share of Semnur stock for every share of Scilex stock held as of the record date of June 1, 2026. However, the payment is subject to change if the Board decides to revoke the dividend or alter the payment date. Scilex holds approximately 186 million shares of Semnur, intending to distribute around 14 million shares to its shareholders.
Read more →SCLXScilex Holding Company (“Scilex”) Announces Its Board of Directors Approved a Dividend of Semnur Pharmaceuticals, Inc. Common Stock to Holders of Scilex Common Stock and other Eligible Equity Securities with a Record Date of June 1, 2026
Scilex Holding Company announced a dividend of Semnur Pharmaceuticals common stock for its shareholders, with a record date set for June 1, 2026. Each holder of Scilex common stock will receive one share of Semnur stock for each share they own. The board retains the right to change the record date and payment conditions, reflecting ongoing financial assessments.
Read more →SCLXScilex Holding Company Announces Its Subsidiaries, ACEA Therapeutics, Inc. and ACEA Pharma, Inc., Entered into a Definitive Agreement with Phoenix Asia Holdings Limited
Scilex Holding Company announced a definitive agreement for its subsidiaries, ACEA Therapeutics and ACEA Pharma, to be acquired by Phoenix Asia Holdings. The deal involves the transfer of 100% equity interests of ACEA Pharma for $1 billion in shares. The acquisition is set to close by the end of Q2 2026, pending regulatory approvals.
Read more →SCLX▲ +5.4%on this news· ran to -24% by day 3shared move
Scilex Holding Company Announces Its Board of Directors Approved May 26, 2026 as the Payment Date of the Previously Announced Dividend of Dream Bowl Meme Coin I Tokens to Record Holders of Common Stock and other Eligible Equity Securities as of the Record Date of April 30, 2026
Scilex Holding Company has announced that its board approved May 26, 2026, as the payment date for a dividend of Dream Bowl Meme Coin I tokens to eligible stockholders. Each holder will receive five tokens for each share of common stock. The company plans to list these tokens on the Biconomy exchange to enhance liquidity. However, the Board retains the right to change the payment date or revoke the dividend.
Read more →SCLX▲ +21.8%on this newsshared move
Dear Scilex Holding Company Stockholders and other holders of Scilex Holding Company Securities: This letter is being furnished to you as a holder of certain securities of Scilex Holding Company, a Delaware corporation (
Scilex Holding Company has announced a dividend of Dream Bowl Meme Coin I tokens for holders of its common stock, warrants, convertible notes, and Series A Preferred Stock as of April 30, 2026. Shareholders must set up a digital wallet with Datavault AI Inc. and complete an Opt-In Agreement to receive the tokens, which are set to be distributed starting May 26, 2026. This dividend is described in the materials sent to all record holders, and more information can be accessed via the company's dedicated Dividend Website.
Read more →SCLXScilex Holding Company Announces Its Board of Directors Approved a Dividend of Dream Bowl I Meme Coin Tokens to Holders of Common Stock and other Eligible Equity Securities with a Record Date of April 30, 2026
Scilex Holding Company has announced a dividend of Dream Bowl I Meme Coin Tokens for its stockholders, with a record date set for April 30, 2026. Eligible holders will receive five tokens per share of common stock. The distribution is subject to the Board's approval and requires holders to set up a digital wallet. The tokens are intended for personal use and do not confer any ownership rights.
Read more →SCLX▼ -6%on this news
KASOWITZ LLP Daniel A. Saunders (SBN 161051) DSaunders@kasowitz.com Robert W. Bosslet (SBN 278027) RBosslet@kasowitz.com 1801 Century Park East, Suite 1830 Los Angeles, California 90067 Telephone: (424) 288-7900 Facsimil
Scilex Holding Company has initiated legal action against multiple defendants, including Marc Wade and Bank of New York Mellon, alleging fraud in a loan agreement that resulted in the sale of pledged securities. The lawsuit claims a conspiracy where the defendants intended to misappropriate stock and manipulate the market value of the shares. Scilex asserts that it has suffered significant financial damage due to these actions, leading to additional accusations of default against the company. The case highlights serious allegations of securities fraud and misrepresentation.
Read more →SCLX▼ -6%on this news
Scilex Holding Company Files Federal Securities Fraud Lawsuit Seeking Recovery of Approximately Ninety-Six (96) Million Misappropriated Collateral Shares of Datavault AI, Inc. from Marc Wade, The St. James Bank & Trust Company Ltd., Omega & Corinth Group Ltd., The Bank of New York Mellon Corporation, and Related Parties
Scilex Holding Company has filed a federal lawsuit against Marc Wade and several financial institutions, alleging the unauthorized sale of approximately 96 million shares of Datavault AI, Inc. The lawsuit details a breach of the stock loan agreement, where shares were sold without consent, leading to substantial financial harm for Scilex. The company is pursuing damages exceeding $100 million, as well as recovery of the misappropriated shares. The allegations indicate potential market impact due to the volume of shares traded unlawfully.
Read more →SCLXScilex Holding Company Announces $20 Million Strategic Investment in Quantum Scan Holdings, Inc., Targeting Trillion-Dollar Preventive Diagnosis and Prognosis Markets
Scilex Holding Company has announced a $20 million strategic investment in Quantum Scan Holdings, Inc. This investment aims to support Quantum Scan's development of advanced diagnostic technologies targeting preventive diagnosis and prognosis markets. The collaboration is expected to enhance healthcare accessibility and efficiency, aligning with Scilex's strategic priorities in non-opioid pain management.
Read more →SCLX▲ +7.3%on this news
Scilex Holding Company Appoints Kasowitz LLP as Litigation and Intellectual Property Counsel
Scilex Holding Company has appointed Kasowitz LLP, led by Marc Kasowitz, as its litigation and intellectual property counsel. This strategic move aims to bolster Scilex's legal capabilities in complex commercial and patent litigation as it advances its non-opioid pain management products. The appointment is seen as crucial for protecting the company's intellectual property and enhancing shareholder value.
Read more →SCLX▼ -8.2%on this news
Scilex Holding Company Confirms Dream Bowl 2026 Meme Coin Claim Process on December 24, 2025 Drop by Datavault AI Inc.
Scilex Holding Company has confirmed the process for claiming Dream Bowl 2026 Meme Coins starting December 24, 2025, utilizing Datavault AI's blockchain technology. Eligible shareholders of record as of November 25, 2025, can participate in the token distribution, which aims to integrate digital assets with sports and shareholder benefits. This initiative represents Scilex's innovative strategy in the evolving digital asset space, promising to boost shareholder engagement and interest.
Read more →SCLXScilex Holding Company Announces Closing of Previously Announced Second Tranche Investment in Datavault AI Inc., Completing Its Two-Tranche Equity Financing in Datavault AI Inc.
Scilex Holding Company has successfully closed the second tranche of its investment in Datavault AI Inc., solidifying a strategic partnership. This investment included purchasing a pre-funded warrant for 263,914,094 shares of Datavault AI, valued at approximately $583.3 million. The closing followed stockholder approval at Datavault's annual meeting and is expected to strengthen collaboration in the realm of Real World Asset tokenization moving forward. Scilex's commitment to expanding its operations aligns with its focus on non-opioid pain management products.
Read more →SCLXScilex Holding Company Announces Closing of Exercise of Warrants for $20.3 Million Gross Proceeds
Scilex Holding Company has successfully closed the exercise of existing warrants, generating approximately $20.3 million in gross proceeds. The company issued new warrants allowing the purchase of additional shares at a reduced exercise price. The funds will be allocated for working capital and general corporate purposes, supporting Scilex's focus on non-opioid pain management solutions.
Read more →SCLXScilex Holding Company Announces Exercise of Warrants for $20.3 Million Gross Proceeds
Scilex Holding Company has announced the exercise of existing warrants, resulting in gross proceeds of approximately $20.3 million. The exercise involves warrants for 428,572 and 475,824 shares at prices of $38.50 and $22.72, respectively. The offering is expected to close on November 25, 2025, and the funds will be used for working capital and general corporate purposes.
Read more →SCLXScilex Holding Company Announces Update Regarding Distribution of Dream Bowl 2026 Meme Coin by Datavault AI Inc.
Scilex Holding Company announced an upcoming distribution of Dream Bowl 2026 Meme Coins by Datavault AI to its common stockholders. This distribution is a token of appreciation for Scilex's partnership with Datavault AI. The distribution will occur on November 25, 2025, but is subject to changes by Datavault AI's Board of Directors regarding the record and payment dates.
Read more →About Scilex Holding Company
Headquarters960 SAN ANTONIO ROAD, PALO ALTO, CA, 94303
BIOPHARMAWATCH ELITE PLUS
Trade the next SCLX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime